MDACC Study No:2012-0588 ( NCT No: NCT01656642)
Title:A Phase Ib, Open-Label Study of the Safety and Pharmacology of MPDL3280A Administered in Combination with Vemurafenib or Vemurafenib Plus Cobimetinib in Patients with Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Principal Investigator:Patrick Hwu
Treatment Agent:MPDL3280A; Vemurafenib
Study Status:Open
Study Description:The goal of this clinical research study is to allow patients in the main study
of Protocol 2012-0588 to continue receiving MPDL3280A and vemurafenib if the
tumor grows.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:MPDL3280A
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Genentech, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Patrick Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults